FDA OKs generic abortion pill, riling the right
The drug in question is a generic version of mifepristone, used to carry out two-thirds of US abortions


What happened
The Food and Drug Administration has approved a second generic version of mifepristone, the drug used in combination with misoprostol to carry out roughly two-thirds of U.S. abortions, drugmaker Evita Solutions announced Thursday. The FDA approved mifepristone in 2000 and the first generic version in 2019.
Who said what
“Approval of a second generic is unlikely to affect access” to mifepristone, The Associated Press said, but the FDA’s quiet approval of Evita’s application “triggered pushback from anti-abortion groups and politicians aligned with the Trump administration.” Students for Life Action called the move “a stain on the Trump presidency and another sign that the deep state at the FDA must go.”
This was the “first significant pushback” President Donald Trump has gotten from his “otherwise loyal base of social conservatives,” The Washington Post said. Less than two weeks ago, anti-abortion activists celebrated a promise from FDA Commissioner Marty Makary and Health and Human Services Secretary Robert F. Kennedy Jr. to review mifepristone’s safety. HHS spokesperson Andrew Nixon said Thursday that “the FDA has very limited discretion in deciding whether to approve a generic drug.”
What next?
“I think the intelligent people in the pro-life movement don’t want to go to war with the administration,” a consultant for anti-abortion groups told the Post. “If you do something that embarrasses Trump and the HSS secretary and the high-profile people, then you wind up with Trump digging in his heels — and you don’t want that.” Evita said it expects its version of mifepristone to become available in January.
The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Peter has worked as a news and culture writer and editor at The Week since the site's launch in 2008. He covers politics, world affairs, religion and cultural currents. His journalism career began as a copy editor at a financial newswire and has included editorial positions at The New York Times Magazine, Facts on File, and Oregon State University.
-
Trump declares ‘armed conflict’ with drug cartels
speed read This provides a legal justification for recent lethal military strikes on three alleged drug trafficking boats
-
October 3 editorial cartoons
Cartoons Friday's political cartoons include changing interest rates, fossil fuel profits, and Bad Bunny singing in Spanish
-
What to know about stablecoins
The Explainer With the government backing calls for the regulation of certain cryptocurrencies, are stablecoins the future?
-
‘Nightmare bacteria’ are rapidly spreading
Under the radar The infections are largely resistant to antibiotics
-
Private equity firms might be causing more deaths in hospital ERs
The Explainer Deaths in ERs purchased by private equity firms rose 13%
-
Trump makes unmoored claims on Tylenol and autism
Speed Read No causal relationship has been established between autism and acetaminophen use during pregnancy
-
RFK Jr. vaccine panel advises restricting MMRV shot
Speed Read The committee voted to restrict access to a childhood vaccine against chickenpox
-
Quit-smoking ads are being put out
Under the radar The dissolution of a government-funded campaign could lead to more smokers in the future
-
Texas declares end to measles outbreak
Speed Read The vaccine-preventable disease is still spreading in neighboring states, Mexico and Canada
-
The truth about sunscreen
The Explainer The science behind influencer claims that sun cream is toxic
-
RFK Jr. shuts down mRNA vaccine funding at agency
Speed Read The decision canceled or modified 22 projects, primarily for work on vaccines and therapeutics for respiratory viruses